Canada markets close in 47 minutes

Kura Oncology, Inc. (KURA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
21.58+0.41 (+1.94%)
As of 03:11PM EDT. Market open.

Kura Oncology, Inc.

12730 High Bluff Drive
Suite 400
San Diego, CA 92130
United States
858 500 8800
https://kuraoncology.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees142

Key Executives

NameTitlePayExercisedYear Born
Dr. Troy Edward Wilson J.D., Ph.D.Chairman, CEO & President1.06MN/A1969
Ms. Kathleen FordChief Operating Officer754.24kN/A1947
Dr. Stephen Dale M.D.Chief Medical Officer684.41kN/A1972
Mr. Thomas DoyleSenior Vice President of Finance & AccountingN/AN/A1971
Mr. Pete De SpainExecutive Vice President of Investor Relations & Corporate CommunicationsN/AN/AN/A
Ms. Teresa Brophy Bair Esq., J.D.Chief Legal Officer & Corporate SecretaryN/AN/A1971
Dr. Roger Bakale Ph.D.Senior Vice President of Manufacturing & Supply ChainN/AN/AN/A
Ms. Maureen Clancy M.B.A.VP and Global Head of Program Leadership & Project ManagementN/AN/AN/A
Dr. Mollie Leoni M.D.Executive Vice President of Clinical DevelopmentN/AN/AN/A
Mr. Brian T. Powl M.B.A., M.S.Chief Commercial OfficerN/AN/A1974
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Corporate Governance

Kura Oncology, Inc.’s ISS Governance QualityScore as of March 1, 2024 is 7. The pillar scores are Audit: 3; Board: 7; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.